News

On June 6, 2025, Smith & Nephew plc announced transactions involving its directors and persons discharging managerial responsibilities (PDMRs) under the company’s Employee Stock Purchase Plan ...
UK medical products maker Smith+Nephew beat first-quarter revenue growth expectations and maintained its full-year sales and profit margin forecasts on Wednesday, despite the potential impact of U ...
Shares in medical firm Smith & Nephew leapt on Tuesday as ongoing restructuring delivered strong full-year sales and profits. At £11.37 per share, Smith & Nephew’s share price was 9% higher on ...
After making his runway debut at Luar’s fall 2024 fashion show, Julez Smith Jr. reunited with the designer, walking in his fall 2025 presentation at New York Fashion Week on Monday. The model ...
Smith & Nephew needs to execute its self-improvement plan effectively to close the value gap and regain investor confidence in its turnaround strategy, particularly in the major joint business.
Smith & Nephew announced it received FDA clearance of its Coriograph preoperative planning and modeling services for use in total hip arthroplasty procedures, according to a company press ...
Smith & Nephew said on Thursday it was confident it was on the right course after the Financial Times reported that three major investors were pushing for a break-up of the medical device maker.
Smith & Nephew SNATS SNN is likely to witness operational improvements in the future as Cevian Capital, a Swedish investment firm, purchased a 5% stake in the company.
Cevian, whose newly disclosed holding would make it Smith & Nephew's second biggest shareholder, is known for taking stakes in businesses and calling for change.
Shares in Smith & Nephew, the renowned manufacturer of knee and hip replacements, jumped significantly after Cevian Capital revealed its 5 per cent stake in the company.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced ...